HER2-positive Gastric Cancer Recruiting Phase 1 Trials for Atezolizumab (DB11595)

IndicationStatusPhase
DBCOND0092590 (HER2-positive Gastric Cancer)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03650348PRS-343 in Combination With Atezolizumab in HER2-Positive Solid TumorsTreatment